Erasca (Erasca) Total Liabilities : $81.61 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Erasca Total Liabilities?

Erasca's Total Liabilities for the quarter that ended in Mar. 2024 was $81.61 Mil.

Erasca's quarterly Total Liabilities declined from Sep. 2023 ($80.43 Mil) to Dec. 2023 ($78.61 Mil) but then increased from Dec. 2023 ($78.61 Mil) to Mar. 2024 ($81.61 Mil).

Erasca's annual Total Liabilities increased from Dec. 2021 ($44.89 Mil) to Dec. 2022 ($103.06 Mil) but then declined from Dec. 2022 ($103.06 Mil) to Dec. 2023 ($78.61 Mil).

Erasca Total Liabilities Historical Data

The historical data trend for Erasca's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Erasca Total Liabilities Chart

Erasca Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

69.12

238.81

44.89

103.06

78.61

Erasca Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial													81.09	77.96	80.43	78.61	81.61

Erasca Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Erasca's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	26.156	+	(51.889	+	0.566
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	78.61

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	395.297	-	316.686
	=	78.61

Erasca's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	30.243	+	(50.811	+	0.559
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	81.61

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	370.022	-	288.409
	=	81.61

Erasca Total Liabilities Related Terms

Thank you for viewing the detailed overview of Erasca's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Erasca (Erasca) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Erasca Inc (NAS:ERAS) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

3115 Merryfield Row, Suite 300, San Diego, CA, USA, 92121

Website

https://www.erasca.com

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Executives

Jonathan E Lim	director, 10 percent owner, officer: See Remarks	11588 SORRENTO VALLEY ROAD, SUITE 17, SAN DIEGO CA 92121
Start Valerie Denise Harding	director	C/O IGNYTA, INC., 11111 FLINTKOTE AVE., SAN DIEGO CA 92121
Alexander W. Casdin	director	C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
Shannon Morris	officer: Chief Medical Officer	C/O ERASCA, INC., 3115 MERRYFIELD ROW, SUITE 300, SAN DIEGO CA 92121
James Arthur Bristol	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Cormorant Asset Management, Lp	director	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen	director	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	director	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Ii, Lp	director	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Jean I Liu	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Pratik S Multani	director	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Julie Hambleton	director	C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Ebun Garner	officer: General Counsel	C/O ALPHATEC HOLDINGS, INC., 2051 PALOMAR AIRPORT ROAD, CARLSBAD CA 92011
Lim Conyee T.	10 percent owner	C/O ERASCA, INC., 10835 ROAD TO THE CURE #140, SAN DIEGO CA 92121
Arch Venture Fund X, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631